Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH2 | P05091 | 2/20 | 0.56 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.56 |
| ▸ | ALDH1B1 | P30837 | 1/20 | 0.56 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600311 | 0.78 | KDM4E (0.58) | PTPN1CYP3A4HSD17B10KDM4ECYP2D6 | |
| SCHEMBL4795310 | 0.78 | PTPN1 (0.53) | PTPN1CYP3A4HSD17B10KDM4ECYP2D6 | |
| SCHEMBL3467047 | 0.76 | CYP3A4 (0.59) | PTPN1CYP3A4HSD17B10KDM4ECYP2D6 | |
| SCHEMBL1115781 | 0.75 | PTPN1 (0.45) | ALDH2PTPN1CYP3A4HSD17B10KDM4E | |
| SCHEMBL10336302 | 0.72 | MAPK1 (0.46) | CYP3A4HSD17B10KDM4ECYP2D6CYP2A6 | |
| SCHEMBL1002679 | 0.72 | CYP3A4 (0.49) | ALDH2ALDH1A2ALDH1B1ALDH1A3CYP3A4 | |
| SCHEMBL9361777 | 0.72 | ALDH1A1 (0.56) | ALDH2ALDH1A2ALDH1B1ALDH1A3PTPN1 | |
| SCHEMBL11036797 | 0.72 | PTPN1 (0.58) | PTPN1CYP3A4HSD17B10KDM4ECYP2D6 | |
| SCHEMBL29621714 | 0.72 | PTPN1 (0.58) | PTPN1CYP3A4HSD17B10KDM4ECYP2D6 | |
| SCHEMBL14134400 | 0.71 | ALDH2 (0.64) | ALDH2ALDH1A2ALDH1B1ALDH1A3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177534-A1 | THERMOSTABLE UV INACTIVATED VACCINES AND OTHER BIOPHARMACEUTICALS | UNIVERSAL STABILIZATION TECHNOLOGIES INC. (US) | 2025-06-05 | — | — | US | disclosed |
| WO-2023164075-A1 | THERMOSTABLE UV INACTIVATED VACCINES AND OTHER BIOPHARMACEUTICALS | UNIVERSAL STABILIZATION TECHNOLOGIES INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20220387517-A1 | FIBROBLAST THERAPY FOR INFLAMMATORY BOWEL DISEASE | FIGENE, LLC | 2022-12-08 | — | — | US | disclosed |
| US-20220370506-A1 | AUGMENTATION OF FIBROBLAST MEDIATED REGENERATION OF INTRAVERTEBRAL DISCS | FIGENE, LLC | 2022-11-24 | — | — | US | disclosed |
| EP-4081261-A1 | AUGMENTATION OF FIBROBLAST MEDIATED REGENERATION OF INTRAVERTEBRAL DISCS | Figene, LLC (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-4058045-A1 | FIBROBLAST THERAPY FOR INFLAMMATORY BOWEL DISEASE | Figene, LLC (US) | 2022-09-21 | — | — | EP | disclosed |
| US-20220168411-A1 | PSORALEN-INACTIVATED CORONAVIRUS VACCINE AND METHOD OF PREPARATION | THE UNITED STATES OF AMERICAN AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2022-06-02 | — | — | US | disclosed |
| US-20160235708-A1 | TOPICAL PIGMENTORY COMPOSITION | BANERJI SANJAY (IN) | 2016-08-18 | — | — | US | disclosed |
| EP-1357912-A2 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QLT Inc. (CA) | 2003-11-05 | — | — | EP | disclosed |
| EP-1032265-B1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORP (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030082510-A1 | Psoralens for pathogen inactivation | CERUS CORPORATION (US) | 2003-05-01 | — | — | US | disclosed |
| WO-2002062386-A2 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QLT INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| EP-1032265-A4 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORP (US) | 2001-05-30 | — | — | EP | disclosed |
| EP-1032265-A1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | Cerus Corporation (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999026476-A1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORPORATION (US) | 1999-06-03 | — | — | WO | disclosed |
| CN-1215305-A | Method for removal of psoralens from biological fluids | THERAKOS INC (US) | 1999-04-28 | — | — | CN | disclosed |
| US-5854967-A | Device and method for photoactivation | CERUS CORPORATION (US) | 1998-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082510-A1 | Psoralens for pathogen inactivation | BPGM, XPA, RAD50 | ALDH2 1672/4885ALDH1A2 911/4885ALDH1B1 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.